Patents Assigned to Seoul National University Hospital
-
Patent number: 10577609Abstract: The present invention relates to a DNA aptamer specifically binding to a hepatocellular carcinoma-related Glypican-3 (GPC3) protein, treatment of cancers related to the Glypican-3 protein using the same, a composition for inhibiting a cancer and a composition for diagnosing a cancer comprising the same as an active ingredient.Type: GrantFiled: March 6, 2017Date of Patent: March 3, 2020Assignees: POSTECH ACADEMY—INDUSTRY FOUNDATION, SEOUL NATIONAL UNIVERSITY HOSPITAL, YONSEI UNIVERSITY, UNIVERSITY—INDUSTRY FOUNDATION (UIF)Inventors: Eun Ju Oh, Jung Hwan Lee, Jong-Hoon Lim, Jong In Kim, Jung Hwan Yoon, Sung Ho Ryu, Jeong-Hoon Lee, Won Jun Kang, Seong Hui Jin
-
Publication number: 20200064258Abstract: A DNA analysis method and a DNA analyzing device using terahertz wave capable of accurately determining a type of cancer from DNA using terahertz wave are disclosed. The DNA analysis method according to the present invention comprises: (a) irradiating terahertz wave onto methylated DNA; (b) detecting the terahertz wave reflected from the methylated DNA; (c) detecting a peak of a waveform of the terahertz wave detected in the step (b); and (d) determining type of cancer from the peak detected in the step (c).Type: ApplicationFiled: November 16, 2017Publication date: February 27, 2020Applicants: UNIVERSITY OF SEOUL INDUSTRY COOPERATION FOUNDATION, SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Joohiuk SON, Hwayeong CHEON, Heejin YANG
-
Patent number: 10570370Abstract: Provided are a method of preparing retinal ganglion cells by differentiation of stem into retinal ganglion cells, retinal ganglion cells differentiated by the method, a method of screening for a death inhibitor or a proliferation promoter of retinal ganglion cells using the retinal ganglion cells differentiated by the method, a kit of screening for the death inhibitor or the proliferation promoter of retinal ganglion cells including the retinal ganglion cells differentiated by the method, a pharmaceutical composition for treating glaucoma or optic neuropathy including the retinal ganglion cells, a method of treating glaucoma or optic neuropathy including the step of administering the retinal ganglion cells to a subject suspected of having glaucoma or optic neuropathy, and a method of preparing a mature retinal ganglion cell line.Type: GrantFiled: August 27, 2015Date of Patent: February 25, 2020Assignees: Seoul National University R&DB Foundation, Seoul National University HospitalInventors: Sung Sup Park, Ji Yeon Kim
-
Patent number: 10464901Abstract: Provided are a compound represented by the following Formula I-1 or I-2, and a composition for preventing or treating dementia or Alzheimer's disease, the composition including the compound and a pharmaceutically acceptable carrier:Type: GrantFiled: January 31, 2018Date of Patent: November 5, 2019Assignees: UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY), SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Mi Hee Lim, Sang Tae Kim, Ho Seong Han
-
Patent number: 10401505Abstract: The present disclosure relates to a contact lens type dosimeter for measuring a dose distribution of a crystalline lens during radiation therapy, and a method of manufacturing the same. The ocular dosimeter has a contact lens shape and is configured to be worn on an eyeball, which comprises a basic material containing hydrophilic polyurethane, and a radiochromic dye. When the ocular dosimeter is worn on the eyeball, the dosimeter is configured to measure a radiation dose irradiated to a crystalline lens through a variation in color of the ocular dosimeter.Type: GrantFiled: October 17, 2018Date of Patent: September 3, 2019Assignee: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Jung In Kim, Jong Min Park, Won Mo Sung, Hong Gyun Wu
-
Publication number: 20190262532Abstract: The present invention relates to systems and methods for controlling flow through the urinary bladder and, more specifically, systems and methods for controlling continuous bladder irrigation after surgical treatment of lower urinary tract disorders. The control system for continuous bladder irrigation includes a catheter having a first port though which a first fluid enters a bladder and a second port through a second fluid exits the bladder; a first flow speed sensor for measuring a first speed of the first fluid; a second flow speed sensor for measuring a second speed of the second fluid; a control unit for sending, based on the first and second speeds, a warning signal of an abnormality in infusing the first fluid into the bladder and in draining the second fluid from the bladder.Type: ApplicationFiled: February 26, 2019Publication date: August 29, 2019Applicant: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Seung-June Oh, Hyoun-Joong Kong
-
Publication number: 20190261846Abstract: A system for controlling a pressure inside a bladder through an endoscope, where the distal end portion of the endoscope is located inside the bladder and the endoscope has an inlet port through which fluid to enter the bladder and an outlet port through which fluid in the bladder to exit the bladder. The system includes one or more processors that receive a first signal from a first pressure sensor installed in a first fluid passageway that is in fluid communication with the inlet port; receives a second signal from a second pressure sensor installed in a second fluid passageway that is in fluid communication with the outlet port; and based on at least one of the first and second signals, actuates a valve installed in the first fluid passageway of fluid so as to adjust the flow rate into the bladder through the inlet port.Type: ApplicationFiled: June 17, 2018Publication date: August 29, 2019Applicant: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Seung-June Oh, Hyoun-Joong Kong
-
Publication number: 20190240161Abstract: Provided are a ceria nanocomposite including a ceria nanoparticle for treating subarachnoid hemorrhage, a method of preparing the same, and a pharmaceutical composition including the ceria nanocomposite. The ceria nanocomposite for treating subarachnoid hemorrhage disclosed herein includes a ceria nanoparticle and a surface modified layer disposed on a surface of the ceria nanoparticle, wherein the surface modified layer includes a polyethylene glycol residue.Type: ApplicationFiled: October 21, 2016Publication date: August 8, 2019Applicants: Cenyx Biotech Inc., Seoul National University Hospital, Research & Business Foundation Sungkyunkwan UniversityInventors: Seung-Hoon Lee, Han-Gil Jeong, Do Yeon Kim, Dong-Wan Kang, Jaeyun Kim, Bong Geun Cha
-
Patent number: 10294453Abstract: The present invention relates to a method for increasing the stemness of human mesenchymal stem cells and, more particularly, to: a method for increasing the stemness of human mesenchymal stem cells by means of endothelin-1 treatment; the human mesenchymal stem cells having increased stemness by using the method; and a composition for increasing the stemness of human mesenchymal stem cells, containing endothelin-1 as an active ingredient. In the present invention, it is confirmed that the expression of a stemness marker is increased and that a stem cell characteristic is improved such as the length of telomeres being extended, by treating human mesenchymal stem cells with endothelin-1, and thus cellular life span is extended, aging is inhibited, and the growth and viability of cells are increased, thereby enabling mass culturing of human mesenchymal stem cells such that human mesenchymal stem cells are expected to be used effectively in cell therapy or regenerative medicine.Type: GrantFiled: November 26, 2015Date of Patent: May 21, 2019Assignee: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Hyo-Soo Kim, Eun Ju Lee
-
Publication number: 20190092728Abstract: Provided are a compound represented by the following Formula I-1 or I-2, and a composition for preventing or treating dementia or Alzheimer's disease, the composition including the compound and a pharmaceutically acceptable carrier:Type: ApplicationFiled: January 31, 2018Publication date: March 28, 2019Applicants: UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY), SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Mi Hee Lim, Sang Tae Kim, Ho Seong Han
-
Publication number: 20190092717Abstract: Provided are a compound represented by the following Formula I, or a solvate, stereoisomer, or pharmaceutically acceptable salt thereof, and a composition for preventing or treating hair loss, the compound including the compound as an active ingredient:Type: ApplicationFiled: January 31, 2018Publication date: March 28, 2019Applicants: UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY), SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Mi Hee Lim, Sang Tae Kim, Ho Seong Han
-
Publication number: 20190091168Abstract: Provided is a transdermal formulation including a transdermal absorption enhancer including an aliphatic hydrocarbon derivative and a pyrrolidone derivative; and a benzene diamine derivative for preventing or treating dementia, Alzheimer's disease, and hair loss.Type: ApplicationFiled: January 31, 2018Publication date: March 28, 2019Applicants: UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY), SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Mi Hee Lim, Sang Tae Kim, Ho Seong Han
-
Publication number: 20190086556Abstract: The present disclosure relates to a contact lens type dosimeter for measuring a dose distribution of a crystalline lens during radiation therapy, and a method of manufacturing the same. The ocular dosimeter has a contact lens shape and is configured to be worn on an eyeball, which comprises a basic material containing hydrophilic polyurethane, and a radiochromic dye. When the ocular dosimeter is worn on the eyeball, the dosimeter is configured to measure a radiation dose irradiated to a crystalline lens through a variation in color of the ocular dosimeter.Type: ApplicationFiled: October 17, 2018Publication date: March 21, 2019Applicant: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Jung In KIM, Jong Min PARK, Won Mo SUNG, Hong Gyun WU
-
Publication number: 20190060668Abstract: The present disclosure relates to a respiratory gating system for inducing respiration of a patient during radiation therapy. A respiratory gating system according to one embodiment of the present disclosure comprises: an image management unit for acquiring an MRI image of a patient and processing the acquired image; and a projection unit for displaying the MRI image acquired and processed by the image management unit to the patient in real time, wherein the projection unit may be configured to project an image of a treatment area of the patient in real time using, as a screen, a bore of a radiotherapy equipment which is formed to surround the patient in order to acquire the MRI image.Type: ApplicationFiled: October 29, 2018Publication date: February 28, 2019Applicants: SEOUL NATIONAL UNIVERSITY HOSPITAL, HANBEAM TECHNOLOGY INC.Inventors: Hong Gyun WU, Jong Min PARK, Chang Heon CHOI, Jung In KIM
-
Patent number: 10208130Abstract: Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-Her2 therapeutic agents. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.Type: GrantFiled: May 31, 2016Date of Patent: February 19, 2019Assignees: Expression Pathology, Inc., Department of Internal Medicine and Cancer Research, Seoul National University HospitalInventors: Yung-Jue Bang, Todd Hembrough, Eunkyung An, Do-Youn Oh
-
Publication number: 20190046528Abstract: Provided herein is a method of preventing hair loss or promoting hair growth, the method including administering an effective amount of a PDE 3 inhibitor. More particularly, when the method of the present disclosure is used, an excellent hair loss prevention or hair growth promotion effect is obtained by inhibiting the activity of PDE 3.Type: ApplicationFiled: July 25, 2018Publication date: February 14, 2019Applicant: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Ohsang KWON, Hye-In CHOI, Seong Jin JO, Kyu Han KIM
-
Publication number: 20180360307Abstract: The present disclosure relates to an apparatus for angiographic optical coherence tomography in the retina or the choroid, and a method for diagnosing diseases by using the same and, more specifically, to: an apparatus for angiographic optical coherence tomography in the retina and the choroid, capable of diagnosing, at an early stage, shock states or diseases such as those of sepsis by quickly and objectively recognizing the low perfusion of tissue; and a diagnostic method using the same.Type: ApplicationFiled: July 31, 2018Publication date: December 20, 2018Applicants: Korea Advanced Institute of Science and Technology, Seoul National University HospitalInventors: Wangyuhl OH, Jang Ryul PARK, Kyuseok KIM
-
Patent number: 9933424Abstract: The present invention concerns a human resistin receptor. More particularly, the present invention provides a method for screening a receptor of human resistin protein, a method for preventing or treating an inflammatory disease and arteriosclerosis using an expression- or activity-regulator for a human resistin receptor, and a pharmaceutical composition including an expression- or activity-regulator for the human resistin receptor. The method for screening a human resistin protein receptor according to the present invention enables separation of a receptor which directly binds to resistin from human monocyte, reveals a mechanism of signal transduction of the resistin receptor, and therefore, is expected to contribute to regulation of an inflammatory effect of monocyte, molecular detection of causes for vascular inflammation and arteriosclerosis, and developments of prevention and a treating agent for an inflammatory disease and arteriosclerosis.Type: GrantFiled: August 7, 2012Date of Patent: April 3, 2018Assignee: Seoul National University HospitalInventors: Young Bae Park, Hyo Soo Kim, Yoo Wook Kwon, Sahmin Lee, Hyun Chae Lee, Young Jin Cho, Sang Eun Lee, Jun Ho Chung
-
Patent number: 9139811Abstract: The present invention relates to a composition for suppressing the death of stem cells during suspension culturing, a composition for mass culturing of stem cells, and a method for suppressing cell death of stem cells during suspension culturing. The composition of the present invention can be usefully used for effective single suspension culturing of stem cells, particularly, mesenchymal stem cells, or used for mass suspension culturing under the circumstances in which cell aggregation does not occur.Type: GrantFiled: December 27, 2011Date of Patent: September 22, 2015Assignee: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Eun Ju Lee, Hyo Soo Kim
-
Patent number: 9050104Abstract: The present invention provides a bipolar radiofrequency ablation catheter comprising a working catheter and a magnetic catheter. The magnetic catheter comprises a first tube; a magnet; a first electrode; and a first electrode connector, and the working catheter comprises a second tube; a metallic element; a second electrode; and a second electrode connector. According to the present invention, it is possible to create transmural lesions more completely and easily at a thick myocardial region such as left ventricle in which a transmural lesion could not be easily created by using conventional radiofrequency ablation catheters and thus it is expected to increase the treatment efficiency for tachycardia such as ventricular tachycardia and atrial fibrillation.Type: GrantFiled: February 9, 2010Date of Patent: June 9, 2015Assignee: SEOUL NATIONAL UNIVERSITY HOSPITALInventor: Seil Oh